- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jawad Saleh: There Are Many Risk Factors for PONV
There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of pharmacy services, Hospital for Special Surgery.
There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of pharmacy services, Hospital for Special Surgery.
Transcript
What are some of the most common risk factors for postoperative nausea and vomiting? How should these risks be assessed to understand treatment?
The risk factors are vast. If you look into it, there's so many risk factors. But based on the Apfel study, if you look at the Apfel simplified risk score—which I actually encourage and it's also encouraged in the consensus guidelines that were recently published—if you're female, that's a risk factor. If you are a nonsmoker, that's a risk factor. If you have a history of PONV or motion sickness, that's a risk factor. And if you're getting opioids, that's a risk factor.
So those are the 4 Apfel simplified risk factors and, honestly, it puts a large number of people in more of a moderate- or high-risk state of PONV. Keeping that in mind, the average PONV rate is 30%; it’s 80% for high-risk patients. At Hospital for Special Surgery, we've been doing an amazing job—we're well below that number. And hopefully, we continue to reduce that number.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More
